TY - JOUR
T1 - Are Ergothioneine Levels in Blood Associated with Chronic Peripheral Neuropathy in Colorectal Cancer Patients Who Underwent Chemotherapy?
AU - Winkels, Renate M.
AU - van Brakel, Lieve
AU - van Baar, Harm
AU - Beelman, Robert B.
AU - van Duijnhoven, Fränzel J.B.
AU - Geijsen, Anne
AU - van Halteren, Henk K.
AU - Hansson, Bibi M.E.
AU - Richie, John P.
AU - Sun, Dongxiao
AU - Wesselink, Evertine
AU - van Zutphen, Moniek
AU - Kampman, Ellen
AU - Kok, Dieuwertje E.
N1 - Funding Information:
The COLON study was financially supported by Wereld Kanker Onderzoek Fonds, including funds from grant 2014/ 1179 as part of the World Cancer Research Fund International Regular Grant Program; Alpe d’Huzes/Dutch Cancer Society (UM 2012-5653, UW 2013-5927, UW 2015-7946); and ERA-NET on Translational Cancer Research (TRANSCAN/Dutch Cancer Society: UW2013-6397, UW2014-6877 and The Netherlands Organization for Health Research and Development (ZonMw, The Netherlands).
PY - 2020/4/2
Y1 - 2020/4/2
N2 - Objective: Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN) is highly prevalent among colorectal cancer (CRC) patients. Ergothioneine (ET)–a dietary antioxidant -protected against CIPN in experimental models, but human studies are lacking. We explored whether whole blood ET levels were associated with chronic peripheral neuropathy among CRC patients who had completed chemotherapy. Methods: At diagnosis, median ET-concentration in whole blood of 159 CRC patients was 10.2 μg/ml (7.2–15.8). Patients completed questionnaires on peripheral neuropathy 6 months after completion of chemotherapy. We calculated prevalence ratios (PR) to assess associations of ET-concentrations and prevalence of peripheral neuropathy and used linear regression to assess associations with severity of peripheral neuropathy. Results: Prevalence of total and sensory peripheral neuropathy were both 81%. Higher ET-concentrations tended to be associated with lower prevalence of total and sensory peripheral neuropathy, but not statistically significant (highest versus lowest tertile of ET: PR = 0.93(0.78, 1.11) for total neuropathy, and PR = 0.84(0.70, 1.02) for sensory neuropathy). ET-concentrations were not associated with severity of neuropathy. Conclusion: Statistically significant associations were not observed, possibly because of limited sample size. Although data may putatively suggest higher levels of ET to be associated with a lower prevalence of neuropathy, analyses should be repeated in larger populations with larger variability in ET-concentrations.
AB - Objective: Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN) is highly prevalent among colorectal cancer (CRC) patients. Ergothioneine (ET)–a dietary antioxidant -protected against CIPN in experimental models, but human studies are lacking. We explored whether whole blood ET levels were associated with chronic peripheral neuropathy among CRC patients who had completed chemotherapy. Methods: At diagnosis, median ET-concentration in whole blood of 159 CRC patients was 10.2 μg/ml (7.2–15.8). Patients completed questionnaires on peripheral neuropathy 6 months after completion of chemotherapy. We calculated prevalence ratios (PR) to assess associations of ET-concentrations and prevalence of peripheral neuropathy and used linear regression to assess associations with severity of peripheral neuropathy. Results: Prevalence of total and sensory peripheral neuropathy were both 81%. Higher ET-concentrations tended to be associated with lower prevalence of total and sensory peripheral neuropathy, but not statistically significant (highest versus lowest tertile of ET: PR = 0.93(0.78, 1.11) for total neuropathy, and PR = 0.84(0.70, 1.02) for sensory neuropathy). ET-concentrations were not associated with severity of neuropathy. Conclusion: Statistically significant associations were not observed, possibly because of limited sample size. Although data may putatively suggest higher levels of ET to be associated with a lower prevalence of neuropathy, analyses should be repeated in larger populations with larger variability in ET-concentrations.
UR - http://www.scopus.com/inward/record.url?scp=85068927095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068927095&partnerID=8YFLogxK
U2 - 10.1080/01635581.2019.1637005
DO - 10.1080/01635581.2019.1637005
M3 - Article
C2 - 31298929
AN - SCOPUS:85068927095
VL - 72
SP - 451
EP - 459
JO - Nutrition and Cancer
JF - Nutrition and Cancer
SN - 0163-5581
IS - 3
ER -